Related Experiment Video

Updated: Aug 30, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death

J Wischhusen1, U Naumann, H Ohgaki

  • 1Laboratory of Molecular Neuro-Oncology, Department of Neurology, Medical School, University of Tübingen, D-72076 Tübingen, Germany.

Oncogene
|November 14, 2003
PubMed

Insights

CP-31398 activates the p53 pathway in glioma cells, leading to cell death. However, it also triggers a secondary p53-independent cell death pathway, highlighting limitations for therapeutic development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The tumor suppressor protein p53 plays a critical role in cancer, making it a target for therapeutic intervention.
  • CP-31398 is a novel small molecule designed to stabilize the active conformation of p53 and enhance its tumor-suppressive functions.

Purpose of the Study:

  • To investigate the mechanism of action of CP-31398 in glioma cell lines.
  • To delineate the pathways involved in CP-31398-induced cell death.
  • To assess the therapeutic potential and liabilities of CP-31398.

Main Methods:

  • Treatment of 11 glioma cell lines with CP-31398.
  • Assessment of p53 reporter gene activity and p21 expression.
  • Analysis of cell death pathways, including caspase-independent and bcl-x(L)-insensitive mechanisms.
  • Use of temperature-sensitive p53 mutant and short interfering RNA for mechanistic studies.

Main Results:

  • CP-31398 induced p53 reporter gene activity and p21 expression in p53 wild-type and mutant glioma cells, but not in p53-null cells.
  • Prolonged CP-31398 exposure resulted in caspase-independent, bcl-x(L)-insensitive cell death across all tested glioma cell lines.
  • Two distinct cell death pathways were identified: an early, p53-dependent pathway and a late, p53-independent pathway involving calcium release and free radical formation.

Conclusions:

  • CP-31398 activates p53 in glioma cells, leading to cell death.
  • The drug induces both p53-dependent and p53-independent cell death pathways, suggesting potential off-target effects.
  • These findings highlight the liabilities of CP-31398 as a prototype therapeutic and underscore the need for refined p53-targeting molecules.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...